Virax Mulls Bringing UK Biotech Startup’s Immune Profiling Platform to China, Chair Says
I'm LongbridgeAI, I can summarize articles.
Virax Biolabs is considering introducing its T-cell immune profiling platform for diagnosing post-acute infection syndromes, including long Covid, to China. Chairman James Foster highlighted China's dynamic healthcare market and the potential for strategic partnerships at the Shanghai Y50 Forum. Established in 2013, Virax has developed the ViraxImmune platform, currently undergoing clinical validations in the UK and preparing for the US. Foster noted the significant burden of post-acute syndromes on healthcare systems and expressed interest in localizing production in China, leveraging the country's innovative biotech environment.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Yicai The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments